Structural Basis for Therapeutic Intervention of uPA/uPAR System

Author(s): Jacky Chi Ki Ngo, Longguang Jiang, Zhonghui Lin, Cai Yuan, Zhuo Chen, Xu Zhang, Haiyang Yu, Jundong Wang, Lin Lin, Mingdong Huang

Journal Name: Current Drug Targets

Volume 12 , Issue 12 , 2011

Become EABM
Become Reviewer
Call for Editor

Abstract:

Urokinase-type plasminogen activator (uPA) is one of the two physiological serine proteases responsible for the activation of plasminongen to plasmin. uPA activity is regulated by its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), and an expanding list of their interacting proteins. In addition to plasminogen activation, this system also plays important roles in the regulation of many cellular processes including cell proliferation, adhesion and migration. It is beyond reasonable doubt that this enzyme system plays a central role in tumor biology and represents a high potential target for therapeutic intervention of tumor growth and metastasis. During the past fifteen years, crystal structures of uPA and its inhibitors have facilitated the development of uPA inhibitors. Many crystal structures of proteins in the uPA/uPAR system have also been reported recently, especially a series of structures of uPAR and its complexes with vitronectin and uPA, facilitating the development and evaluation of uPAR inhibitors. Recent progress on uPA inhibitors will be summarized in this article. The unique structural features and the druggable potentials of these new structures will also be discussed.

Keywords: uPA, uPAR, SMB crystal structures, inhibitors, crystal structures, inhibitors, serine proteases, plasminogen activation, antagonist, tumor, signaling

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 12
Year: 2011
Page: [1729 - 1743]
Pages: 15
DOI: 10.2174/138945011797635911
Price: $65

Article Metrics

PDF: 26